1
|
Dauki A, Lei H, Yonghua L, Sekhon A, Kendra KL, Cavaliere R, WELLIVER MXU, McGregor J, Wei L, Mrozek E, Olencki T, Thelen J, Prevedello D, Thoman W, Matharbootham M, Ammirati M, Coss CC, Grecula JC, Phelps MA. Drug quantification in metastatic brain tumors in patients receiving bendamustine as a radiosensitizer for stereotactic radiotherapy. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.e14017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - He Lei
- Ohio State University, Columbus, OH, US
| | | | | | - Kari Lynn Kendra
- The Ohio State University Comprehensive Cancer Center, Department of Internal Medicine, Columbus, OH
| | | | | | | | - Lai Wei
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - Ewa Mrozek
- The Ohio State University Medical Center James Comprehensive Cancer Center, Columbus, OH
| | - Thomas Olencki
- Ohio State University Wexner Medical Center, Columbus, OH
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
He L, Grecula JC, Ling Y, Enzerra MD, Ammirati M, Kendra K, Cavaliere R, Mayr N, McGregor J, Olencki T, Mrozek E, Matharbootham M, Oluigbo C, Phelps MA. Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 905:141-4. [PMID: 22925718 PMCID: PMC3856370 DOI: 10.1016/j.jchromb.2012.08.013] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2012] [Revised: 08/08/2012] [Accepted: 08/10/2012] [Indexed: 01/09/2023]
Abstract
A liquid chromatography-tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue was developed and fully validated. Methanol was used to precipitate proteins in brain tissue. Bendamustine and internal standard (chlorambucil) were separated with reverse-phase chromatography on a C-18 column with a gradient of water and 95% methanol in 0.1% formic acid. Positive mode electrospray ionization was applied with selected reaction monitoring to achieve 5 ng/ml lower limits of quantitation in mouse brain tissue. The calibration curve for bendamustine in mouse brain was linear between 5 and 2000 ng/ml. The within- and between-batch accuracy and precision of the assay were within 15% at 10, 100 and 1000 ng/ml. The recovery and matrix effect of bendamustine in mouse brain tissue ranged from 41.1% to 51.6% and 107.4% to 110.3%, respectively. The validated method was then applied to quantitate bendamustine in an animal study. Results indicate the assay can be applied to evaluate bendamustine disposition in mouse brain tissue. This assay will be applied in the future to detect and quantify bendamustine in human brain tissue samples.
Collapse
Affiliation(s)
- Lei He
- Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio
| | - John C. Grecula
- Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
- Department of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, Ohio
| | - Yonghua Ling
- Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
| | - Michael D. Enzerra
- Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio
| | - Mario Ammirati
- Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
- Department of Neurosurgery, College of Medicine, The Ohio State University, Columbus, Ohio
| | - Kari Kendra
- Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
- Department of Medicine, College of Medicine, The Ohio State University, Columbus, Ohio
| | - Robert Cavaliere
- Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
- Department of Neurosurgery, College of Medicine, The Ohio State University, Columbus, Ohio
| | - Nina Mayr
- Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
- Department of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, Ohio
| | - John McGregor
- Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
- Department of Neurosurgery, College of Medicine, The Ohio State University, Columbus, Ohio
| | - Thomas Olencki
- Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
- Department of Medicine, College of Medicine, The Ohio State University, Columbus, Ohio
| | - Ewa Mrozek
- Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
- Department of Medicine, College of Medicine, The Ohio State University, Columbus, Ohio
| | - Mani Matharbootham
- Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
- Department of Anesthesiology, College of Medicine, The Ohio State University, Columbus, Ohio
| | - Chima Oluigbo
- Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
- Department of Neurosurgery, College of Medicine, The Ohio State University, Columbus, Ohio
| | - Mitch A. Phelps
- Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio
- Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
| |
Collapse
|